Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models

Tumor hypoxia is a major cause of treatment failure for a variety of malignancies. However, hypoxia offers treatment opportunities, exemplified by the development of compounds that target hypoxic regions within tumors. Evofosfamide (TH‐302) is a prodrug created by the conjugation of 2‐nitroimidazole...

Descripción completa

Detalles Bibliográficos
Autores principales: Liapis, Vasilios, Zinonos, Irene, Labrinidis, Agatha, Hay, Shelley, Ponomarev, Vladimir, Panagopoulos, Vasilios, Zysk, Aneta, DeNichilo, Mark, Ingman, Wendy, Atkins, Gerald J., Findlay, David M., Zannettino, Andrew C. W., Evdokiou, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799961/
https://www.ncbi.nlm.nih.gov/pubmed/26749324
http://dx.doi.org/10.1002/cam4.599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799961/
https://www.ncbi.nlm.nih.gov/pubmed/26749324
http://dx.doi.org/10.1002/cam4.599

Ejemplares similares